pDONR223-EEF2K Citations (3)

Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal

---

Articles Citing pDONR223-EEF2K

Articles
Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells. Xie CM, Liu XY, Sham KW, Lai JM, Cheng CH. Autophagy. 2014 Sep;10(9):1495-508. doi: 10.4161/auto.29164. Epub 2014 Jun 19. PubMed
Pharmacological eEF2K activation promotes cell death and inhibits cancer progression. De Gassart A, Demaria O, Panes R, Zaffalon L, Ryazanov AG, Gilliet M, Martinon F. EMBO Rep. 2016 Oct;17(10):1471-1484. Epub 2016 Aug 29. PubMed
ZRF1 is a novel S6 kinase substrate that drives the senescence programme. Barilari M, Bonfils G, Treins C, Koka V, De Villeneuve D, Fabrega S, Pende M. EMBO J. 2017 Mar 15;36(6):736-750. doi: 10.15252/embj.201694966. Epub 2017 Feb 27. PubMed

If you have published an article using this material, please email us at to have your article added to this page.